AstraZeneca (AZN) and Eli Lilly (LLY) became the latest Tuesday in a series of pharmaceutical ... Researchers believe the toxic substance is at the center of …
Want to be alerted before Jim Cramer buys or sells the stock? Learn more now. …
Alzheimer’s, a fatal illness that causes progressive decline in memory, has always been a highly challenging area with not much progress being made in spite of …
(MENAFN Editorial) INDIANAPOLIS, June 5, 2018 /PRNewswire/ --Eli Lilly and …
JAK inhibitors were in the news this week with Eli Lilly (NYSE: LLY) finally gaining FDA approval for its rheumatoid arthritis ("RA") candidate Olumiant (baricitinib) in the United States while AbbVie (NYSE: ABBV) presented positive top-line …
The rating was maintained by Jefferies with “Buy” on Friday, March 23. The stock of Eli Lilly and Company (NYSE:LLY) has “Hold” rating given on Thursday, February 1 by Leerink Swann. Barclays Capital maintained the shares of LLY in …
Merck’s supplemental Biologics License Application (“sBLA”) seeking continued …
INDIANAPOLIS, June 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has learned of an unsolicited mini …